Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes - PubMed (original) (raw)
Site-specific GlcNAcylation of human erythrocyte proteins: potential biomarker(s) for diabetes
Zihao Wang et al. Diabetes. 2009 Feb.
Abstract
Objective: O-linked N-acetylglucosamine (O-GlcNAc) is upregulated in diabetic tissues and plays a role in insulin resistance and glucose toxicity. Here, we investigated the extent of GlcNAcylation on human erythrocyte proteins and compared site-specific GlcNAcylation on erythrocyte proteins from diabetic and normal individuals.
Research design and methods: GlcNAcylated erythrocyte proteins or GlcNAcylated peptides were tagged and selectively enriched by a chemoenzymatic approach and identified by mass spectrometry. The enrichment approach was combined with solid-phase chemical derivatization and isotopic labeling to detect O-GlcNAc modification sites and to compare site-specific O-GlcNAc occupancy levels between normal and diabetic erythrocyte proteins.
Results: The enzymes that catalyze the cycling (addition and removal) of O-GlcNAc were detected in human erythrocytes. Twenty-five GlcNAcylated erythrocyte proteins were identified. Protein expression levels were compared between diabetic and normal erythrocytes. Thirty-five O-GlcNAc sites were reproducibly identified, and their site-specific O-GlcNAc occupancy ratios were calculated.
Conclusions: GlcNAcylation is differentially regulated at individual sites on erythrocyte proteins in response to glycemic status. These data suggest not only that site-specific O-GlcNAc levels reflect the glycemic status of an individual but also that O-GlcNAc site occupancy on erythrocyte proteins may be eventually useful as a diagnostic tool for the early detection of diabetes.
Figures
FIG. 1.
Erythrocytic proteins are O-GlcNAc modified. Fifteen micrograms of erythrocyte proteins (hemoglobin depleted) were run on a 12.5% SDS-PAGE gel, transferred, and immunoblotted with antibodies against O-GlcNAc (A), O-GlcNAcase (B, top), or OGT (B, bottom). Different lanes represent samples from different individuals.
FIG. 2.
Enrichment and identification of O-GlcNAc–modified erythrocytic proteins. A: Scheme for enriching O-GlcNAc proteins. B: Negative control of the approach. C: Confirmation of the O-GlcNAc states on several proteins.
FIG. 3.
Mapping O-GlcNAc sites and site-specific quantitation. A: Scheme for enrichment of O-GlcNAc peptides. B: Structure (inset) and CAD fragmentation of fully tagged O-GlcNAc peptide (YSPgTSPSK). [M+GlcNAc+GalNAz+Biotin+3H]3+ = 614.6, [M+H]+ = 866.5, [M+GlcNAc+H]+ = 1069.6. C: Flow chart for comparing site-specific O-GlcNAc RORs. Inset: Scheme for solid-phase BEMAD. D: Protein expression level dynamics in diabetic erythrocytes compared with normal erythrocytes. E: Specificity control for the enrichment and site-mapping. Samples were untreated or treated with hexosaminidase at 37°C for 48 h before going through the work flow. Base peak chromatograms are shown. NL, intensity in counts normalized to 1 s; TBTA, Tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine; TCEP, Tris(2-carboxyethyl)phosphine.
FIG. 4.
O-GlcNAc as potential biomarkers for diabetes. Specific O-GlcNAc sites (underlined Ser) on ankyrin-1 (identified and quantified by QSTAR) and catalase (identified by LTQ-Orbitrap) were upregulated 2.7- and 3.9-fold, respectively. A: Extracted ion chromatogram (XIC). B: Averaged full-scan spectra during elution time of the ion pairs. C: MS/MS spectra that showed the peptide sequences and mapped DTT attachment sites.
Similar articles
- Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes.
Park K, Saudek CD, Hart GW. Park K, et al. Diabetes. 2010 Jul;59(7):1845-50. doi: 10.2337/db09-1086. Epub 2010 Apr 22. Diabetes. 2010. PMID: 20413512 Free PMC article. - Cross-talk between GlcNAcylation and phosphorylation: roles in insulin resistance and glucose toxicity.
Copeland RJ, Bullen JW, Hart GW. Copeland RJ, et al. Am J Physiol Endocrinol Metab. 2008 Jul;295(1):E17-28. doi: 10.1152/ajpendo.90281.2008. Epub 2008 Apr 29. Am J Physiol Endocrinol Metab. 2008. PMID: 18445751 Free PMC article. Review. - Elevation of the post-translational modification of proteins by O-linked N-acetylglucosamine leads to deterioration of the glucose-stimulated insulin secretion in the pancreas of diabetic Goto-Kakizaki rats.
Akimoto Y, Hart GW, Wells L, Vosseller K, Yamamoto K, Munetomo E, Ohara-Imaizumi M, Nishiwaki C, Nagamatsu S, Hirano H, Kawakami H. Akimoto Y, et al. Glycobiology. 2007 Feb;17(2):127-40. doi: 10.1093/glycob/cwl067. Epub 2006 Nov 9. Glycobiology. 2007. PMID: 17095531 - O-linked beta-N-acetylglucosamine (O-GlcNAc): Extensive crosstalk with phosphorylation to regulate signaling and transcription in response to nutrients and stress.
Butkinaree C, Park K, Hart GW. Butkinaree C, et al. Biochim Biophys Acta. 2010 Feb;1800(2):96-106. doi: 10.1016/j.bbagen.2009.07.018. Epub 2009 Aug 6. Biochim Biophys Acta. 2010. PMID: 19647786 Free PMC article. Review. - O-GlcNAcylation site mapping by (azide-alkyne) click chemistry and mass spectrometry following intensive fractionation of skeletal muscle cells proteins.
Deracinois B, Camoin L, Lambert M, Boyer JB, Dupont E, Bastide B, Cieniewski-Bernard C. Deracinois B, et al. J Proteomics. 2018 Aug 30;186:83-97. doi: 10.1016/j.jprot.2018.07.005. Epub 2018 Jul 26. J Proteomics. 2018. PMID: 30016717
Cited by
- O-GlcNAc modification blocks the aggregation and toxicity of the protein α-synuclein associated with Parkinson's disease.
Marotta NP, Lin YH, Lewis YE, Ambroso MR, Zaro BW, Roth MT, Arnold DB, Langen R, Pratt MR. Marotta NP, et al. Nat Chem. 2015 Nov;7(11):913-20. doi: 10.1038/nchem.2361. Epub 2015 Oct 12. Nat Chem. 2015. PMID: 26492012 Free PMC article. - O-GlcNAc modification inhibits the calpain-mediated cleavage of α-synuclein.
Levine PM, De Leon CA, Galesic A, Balana A, Marotta NP, Lewis YE, Pratt MR. Levine PM, et al. Bioorg Med Chem. 2017 Sep 15;25(18):4977-4982. doi: 10.1016/j.bmc.2017.04.038. Epub 2017 Apr 29. Bioorg Med Chem. 2017. PMID: 28487126 Free PMC article. - Role of _O_-Linked _N_-Acetylglucosamine Protein Modification in Cellular (Patho)Physiology.
Chatham JC, Zhang J, Wende AR. Chatham JC, et al. Physiol Rev. 2021 Apr 1;101(2):427-493. doi: 10.1152/physrev.00043.2019. Epub 2020 Jul 30. Physiol Rev. 2021. PMID: 32730113 Free PMC article. Review. - O-GlcNAcylation and neurodegeneration.
Wani WY, Chatham JC, Darley-Usmar V, McMahon LL, Zhang J. Wani WY, et al. Brain Res Bull. 2017 Jul;133:80-87. doi: 10.1016/j.brainresbull.2016.08.002. Epub 2016 Aug 4. Brain Res Bull. 2017. PMID: 27497832 Free PMC article. Review. - In vivo tagging and characterization of S-glutathionylated proteins by a chemoenzymatic method.
Chiang BY, Chou CC, Hsieh FT, Gao S, Lin JC, Lin SH, Chen TC, Khoo KH, Lin CH. Chiang BY, et al. Angew Chem Int Ed Engl. 2012 Jun 11;51(24):5871-5. doi: 10.1002/anie.201200321. Epub 2012 May 3. Angew Chem Int Ed Engl. 2012. PMID: 22555962 Free PMC article. No abstract available.
References
- Love DC, Hanover JA: The hexosamine signaling pathway: deciphering the “O-GlcNAc code”. Sci STKE 2005: re13, 2005 - PubMed
- Hart GW, Housley MP, Slawson C: Cycling of O-linked beta-N-acetylglucosamine on nucleocytoplasmic proteins. Nature 446: 1017–1022, 2007 - PubMed
- Wells L, Vosseller K, Hart GW: Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science 291: 2376–2378, 2001 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R21 DK071280/DK/NIDDK NIH HHS/United States
- N01-HV-28180/HV/NHLBI NIH HHS/United States
- N01HV28180/HV/NHLBI NIH HHS/United States
- HHMI/Howard Hughes Medical Institute/United States
- R33 DK071280/DK/NIDDK NIH HHS/United States
- DK-71280/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases